发明授权
US09216200B2 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
有权
使用人胎盘灌注液和人胎盘来源的中间体天然杀伤细胞进行肿瘤抑制
- 专利标题： Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
- 专利标题（中）： 使用人胎盘灌注液和人胎盘来源的中间体天然杀伤细胞进行肿瘤抑制
-
申请号： US13584612申请日： 2012-08-13
-
公开(公告)号： US09216200B2公开(公告)日： 2015-12-22
- 发明人: Robert J. Hariri , Mohammad A. Heidaran , Lin Kang , Neerav Dilip Padliya , Ajai Pal , Vanessa Voskinarian-Berse , Andrew Zeitlin , Xiaokui Zhang
- 申请人： Robert J. Hariri , Mohammad A. Heidaran , Lin Kang , Neerav Dilip Padliya , Ajai Pal , Vanessa Voskinarian-Berse , Andrew Zeitlin , Xiaokui Zhang
- 申请人地址： US NJ Warren
- 专利权人： Anthrogenesis Corporation
- 当前专利权人： Anthrogenesis Corporation
- 当前专利权人地址： US NJ Warren
- 代理机构： Jones Day
- 主分类号： A01N63/00
- IPC分类号： A01N63/00 ; A61K35/17 ; A61K35/50 ; C12N5/0783 ; A61K35/12
摘要：
Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
公开/授权文献
信息查询
